QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:CYAD

Celyad Oncology - CYAD Stock Forecast, Price & News

$1.35
0.00 (0.00%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.32
$1.49
50-Day Range
$0.49
$2.37
52-Week Range
$0.46
$3.63
Volume
78,929 shs
Average Volume
4.53 million shs
Market Capitalization
$30.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.78

CYAD stock logo

About Celyad Oncology (NASDAQ:CYAD) Stock

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

CYAD Stock News Headlines

Celyad Oncology SA (CYAD)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Celyad Oncology SA
Celyad Oncology Provides Strategic Update
Celyad: Probably Still Top-Notch In Oncology
Celyad Oncology Announces Leadership Updates
Celyad Oncology reports Q1 results
See More Headlines
Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

CYAD Company Calendar

Today
1/31/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYAD
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.78
High Stock Price Forecast
$2.78
Low Stock Price Forecast
$2.78
Forecasted Upside/Downside
+105.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$2.29 per share

Miscellaneous

Free Float
22,382,000
Market Cap
$30.50 million
Optionable
Not Optionable
Beta
1.38

Key Executives

  • Michel E. Lussier
    Chief Executive Officer & Executive Director
  • David Georges
    Vice President-Finance & Administration
  • Eytan Breman
    Director-Research & Development
  • Frederic Lehmann
    VP-Clinical Development & Medical Affairs
  • David Gilham
    Chief Scientific Officer













CYAD Stock - Frequently Asked Questions

Should I buy or sell Celyad Oncology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celyad Oncology in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CYAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYAD, but not buy additional shares or sell existing shares.
View CYAD analyst ratings
or view top-rated stocks.

What is Celyad Oncology's stock price forecast for 2023?

2 analysts have issued 1 year price objectives for Celyad Oncology's shares. Their CYAD share price forecasts range from $2.78 to $2.78. On average, they expect the company's share price to reach $2.78 in the next year. This suggests a possible upside of 91.7% from the stock's current price.
View analysts price targets for CYAD
or view top-rated stocks among Wall Street analysts.

How have CYAD shares performed in 2023?

Celyad Oncology's stock was trading at $0.4929 at the beginning of the year. Since then, CYAD shares have increased by 194.2% and is now trading at $1.45.
View the best growth stocks for 2023 here
.

When is Celyad Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our CYAD earnings forecast
.

What other stocks do shareholders of Celyad Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).

When did Celyad Oncology IPO?

(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

What is Celyad Oncology's stock symbol?

Celyad Oncology trades on the NASDAQ under the ticker symbol "CYAD."

How do I buy shares of Celyad Oncology?

Shares of CYAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celyad Oncology's stock price today?

One share of CYAD stock can currently be purchased for approximately $1.45.

How much money does Celyad Oncology make?

Celyad Oncology (NASDAQ:CYAD) has a market capitalization of $32.76 million and generates $10,000.00 in revenue each year.

How can I contact Celyad Oncology?

Celyad Oncology's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The official website for the company is www.celyad.com. The company can be reached via phone at (210) 039-4100 or via fax at 321-039-4141.

This page (NASDAQ:CYAD) was last updated on 1/31/2023 by MarketBeat.com Staff